数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   ORKA
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

股本结构

单位：万股
公告日期 2026-08-10 2026-08-10 2026-05-13 2026-04-17 2026-05-13 2026-04-17
证券总股本 6620.97 6106.99 6031.21 5019.69 5016.76 4909.69
普通股本 6620.97 6106.99 6031.21 5019.69 5016.76 4909.69
优先股 未披露 13.71 未披露 未披露 13.71 未披露
其他 未披露 未披露 未披露 未披露 未披露 未披露
变动日期 2026-07-31 2026-06-30 2026-04-30 2026-04-07 2026-03-31 2026-02-15
注释：中概股证券总股本=普通股股本/ 存托凭证比例

历史变动

公告日期 变动后普通股本（万股） 变动后优先股（万股） 变动原因 变动日期
2026-08-10 6620.97 未披露 定期报告 2026-07-31
2026-08-10 6106.99 13.71
更多>>
From March 31,2026 to June 30,2026 Cancellation of unvested restricted stock awards Issuance of common stock under employee stock purchase plan Issuance of common stock under the April 2026 Offering, net of offering costs Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of stock options and employee warrants Issuance of common stock upon vesting of restricted stock units
2026-06-30
2026-05-13 6031.21 未披露 定期报告 2026-04-30
2026-04-17 5019.69 未披露 定期报告 2026-04-07
2026-05-13 5016.76 13.71
更多>>
From December 31,2025 to March 31, 2026 Issuance of common stock upon exercise of stock options and employee warrants Issuance of common stock under the at-the-market (“ATM”) offering program, net of commissions Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon exercise of prefunded warrants
2026-03-31
2026-03-12 4954.27 未披露 定期报告 2026-02-28
2026-04-17 4909.69 未披露 定期报告 2026-02-15
2026-03-12 4872.23 13.71
更多>>
From December 31, 2024 to December 31, 2025 Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of stock options and employee warrants Issuance of common stock under employee stock purchase plan Cancellation of restricted stock awards
2025-12-31
2025-11-12 4840.92 未披露 定期报告 2025-10-31
2025-11-12 4838.42 13.71
更多>>
From June 30, 2025 to September 30, 2025 Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing
2025-09-30
2025-09-22 4838.42 未披露 定期报告 2025-09-19
2025-08-11 3745.07 13.71
更多>>
From March 31, 2025 to June 30, 2025 Issuance of common stock under employee stock purchase plan
2025-06-30
2025-03-06 3744.05 13.71
更多>>
From February 6, 2024 to December 31, 2024 Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization Issuance of Series A convertible preferred stock, net of issuance costs of $69 Conversion of Series A non-voting convertible preferred stock to common stock Issuance of common stock under employee stock purchase plan
2024-12-31
2024-11-13 3499.86 13.96
更多>>
From June 30, 2024 to September 30, 2024 Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing
2024-09-30
2024-09-13 3499.86 0.24 定期报告 2024-09-13
2024-08-23 2949.04 未披露
更多>>
every 12 shares of the combined company’s common stock outstanding will be combined and reclassified into 1 share of the combined company’s common stock
2024-09-03
2024-04-25 1450.71 未披露 定期报告 2024-04-24
2024-02-01 1450.11 未披露
更多>>
From December 31, 2022 to December 31,2023 Issuance of common stock upon vesting of Restricted Stock Units
2023-12-31
2021-03-22 1441.01 未披露 定期报告 2021-03-18
2021-03-18 1441.01 未披露 定期报告 2021-03-01
2021-03-18 954.82 未披露
更多>>
From December 31, 2019 to December 31, 2020 Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
2020-12-31
2020-10-28 932.15 未披露 定期报告 2020-10-14
2020-11-02 928.56 未披露
更多>>
From June 30, 2020 to September 30, 2020 Issuance of common stock for cash,net of offering costs
2020-09-30
2020-08-05 590.53 未披露 定期报告 2020-07-31
2020-07-22 448.19 未披露 定期报告 2020-07-21
2020-07-14 340.34 未披露 定期报告 2020-07-13
2020-08-05 226.76 未披露
更多>>
From March 31, 2020 to June 30, 2020 Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
2020-06-30
2020-06-03 194.21 未披露
更多>>
1.Common Stock Offered By the company 348,000 shares 2.The above discussion and table are based on 1,594,070 shares of common stock outstanding as of June 2, 2020
2020-06-03
2020-07-14 159.41 未披露 定期报告 2020-05-06
2019-11-06 159.41 未披露
更多>>
from June 30, 2019 to September 30, 2019 Issuance of common stock for cash,net of offering costs
2019-09-30
2019-08-01 145.56 未披露
更多>>
from March 31, 2019 to June 30,2019 Issuance of common stock for cash,net of offering costs
2019-06-30
2019-06-28 156.36 未披露 定期报告 2019-06-27
2019-05-20 141.35 未披露 定期报告 2019-05-20
2019-05-20 130.38 未披露 定期报告 2019-05-17
2019-05-09 125.81 未披露 定期报告 2019-05-08
2019-05-08 109.88 未披露
更多>>
from December 31, 2018 to April 4, 2019 Issuance of common stock for cash, net of offering costs Adjustment for fractional shares On April 3, 2019, ARCA biopharma, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Amendment”), to implement an eighteen-for-one reverse split of its common stock (the “Reverse Split”), as previously authorized and approved at a special meeting of the Company’s stockholders on October 18, 2018. The Reverse Split will be effective as of 5:01 p.m. (Eastern Time) on April 3, 2019, and the Company’s common stock will continue trading on the Nasdaq Capital Market on a post-split basis on April 4, 2019.
2019-04-04
2019-02-27 1835.51 未披露 定期报告 2019-02-22
2019-02-27 1392.41 未披露
更多>>
from December 31, 2017 to December 31, 2018 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
2018-12-31
2018-11-14 1392.41 未披露 定期报告 2018-11-12
2018-05-08 1392.38 未披露
更多>>
From December 31, 2017 to April 4, 2018 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
2018-04-04
2018-05-08 1391.43 未披露
更多>>
from December 31, 2017 to March 19, 2018 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
2018-03-19
2018-03-22 1177.51 未披露
更多>>
from December 31, 2016 to December 31, 2017 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
2017-12-31
2017-11-09 1175.10 未披露 定期报告 2017-11-07
2017-11-09 1175.07 未披露
更多>>
from December 31, 2016 to July 31,2017 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
2017-07-31
2017-08-03 1011.66 未披露
更多>>
From December 31, 2016 to June 30, 2017 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
2017-06-30
2017-05-15 924.23 未披露 定期报告 2017-05-11
2017-04-21 918.24 未披露 定期报告 2017-04-10
2017-05-15 917.29 未披露
更多>>
from December 31, 2016 to March 31, 2017 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
2017-03-31
2017-03-21 913.09 未披露 定期报告 2017-03-17
2017-03-21 908.24 未披露
更多>>
from December 31, 2015 to December 31, 2016 Issuance of common stock upon vesting of Restricted Stock Units
2016-12-31
2016-11-14 908.24 未披露 定期报告 2016-11-10
2016-11-14 908.07 未披露
更多>>
From December 31,2015 to September 30, 2016 Issuance of common stock upon vesting of Restricted Stock Units
2016-09-30
2016-04-27 906.63 未披露 定期报告 2016-04-12
2016-05-11 905.66 未披露
更多>>
from December 31, 2015 to March 15, 2016 Issuance of common stock upon vesting of Restricted Stock Units
2016-03-15
2016-03-17 905.12 未披露
更多>>
from December 31, 2014 to December 31, 2015 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units Adjustment for fractional shares On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
2015-12-31
2015-11-12 905.12 未披露 定期报告 2015-11-10
2015-11-12 904.98 未披露
更多>>
From December 31, 2014 to September 30, 2015 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units Adjustment for fractional shares On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
2015-09-30
2015-11-12 903.14 未披露
更多>>
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
2015-09-04
2015-08-11 6322.00 未披露
更多>>
from December 31, 2014 to June 30, 2015 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units On June 16, 2015, we issued to the selling stockholders named below an aggregate of 42,021,579 shares of common stock and warrants to purchase an additional 16,808,632 shares of common stock in a private placement.
2015-06-30
2015-05-12 2119.84 未披露
更多>>
from December 31, 2014 to March 17, 2015 Issuance of common stock upon vesting of Restricted Stock Units
2015-03-17
2014-11-12 2115.05 未披露 定期报告 2014-11-10
2014-11-12 2114.05 未披露
更多>>
from December 31, 2013 to September 30, 2014 Issuance of common stock for cash, net of offering costs Issuance of common stock upon exercise of warrants for cash Issuance of common stock upon vesting of Restricted Stock Awards
2014-09-30
2014-08-13 2101.08 未披露
更多>>
From December 31, 2013 to May 9, 2014 Issuance of common stock for cash,net of offering costs Issuance of common stock upon exercise of warrants for cash
2014-05-09
2014-03-20 2097.98 未披露 定期报告 2014-03-17
2013-11-13 1567.56 未披露 定期报告 2013-11-08
2013-11-13 1319.54 2.49
更多>>
from December 31, 2012 to September 30, 2013 Issuance of common stock for cash, net of offering costs Adjustment for fractional shares Issuance of common stock upon exercise of warrants for cash Issuance of Series A convertible preferred stock, net of offering costs Conversion of preferred stock to common stock On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
2013-09-30
2013-08-13 1095.08 未披露 定期报告 2013-08-09
2013-08-01 1036.09 5.32 定期报告 2013-07-30
2013-08-13 1009.62 5.59
更多>>
from December 31, 2012 to June 30, 2013 Issuance of common stock for cash, net of offering costs Adjustment for fractional shares Issuance of common stock upon exercise of warrants for cash Issuance of Series A convertible preferred stock, net of offering costs Conversion of preferred stock to common stock On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
2013-06-30
2013-02-01 320.00 未披露
更多>>
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.The reverse stock split reduced the number of shares of ARCA’s issued and outstanding common stock from approximately 19.1 million shares to approximately 3.2 million shares.
2013-03-05
2004-02-20 2099.35 未披露
更多>>
1:3 stock split
2004-02-23
From March 31,2026 to June 30,2026 Cancellation of unvested restricted stock awards Issuance of common stock under employee stock purchase plan Issuance of common stock under the April 2026 Offering, net of offering costs Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of stock options and employee warrants Issuance of common stock upon vesting of restricted stock units
From December 31,2025 to March 31, 2026 Issuance of common stock upon exercise of stock options and employee warrants Issuance of common stock under the at-the-market (“ATM”) offering program, net of commissions Issuance of common stock upon vesting of restricted stock units Issuance of common stock upon exercise of prefunded warrants
From December 31, 2024 to December 31, 2025 Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing Issuance of common stock upon exercise of pre-funded warrants Issuance of common stock upon exercise of stock options and employee warrants Issuance of common stock under employee stock purchase plan Cancellation of restricted stock awards
From June 30, 2025 to September 30, 2025 Issuance of common stock and pre-funded warrants in connection with the 2025 PIPE Financing
From March 31, 2025 to June 30, 2025 Issuance of common stock under employee stock purchase plan
From February 6, 2024 to December 31, 2024 Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Exchange of Series A convertible preferred stock for Series B non-voting convertible preferred stock upon the closing of the reverse capitalization Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of reverse recapitalization Issuance of Series A convertible preferred stock, net of issuance costs of $69 Conversion of Series A non-voting convertible preferred stock to common stock Issuance of common stock under employee stock purchase plan
From June 30, 2024 to September 30, 2024 Conversion of convertible notes (including accrued interest) into common stock upon the closing of the reverse recapitalization Issuance of common stock and pre-funded warrants in the Pre-Closing Financing Issuance of common stock to former stockholders of ARCA biopharma, Inc. in connection with the closing of the reverse recapitalization Issuance of common stock, Series A non-voting convertible preferred stock, and pre-funded warrants in connection with the PIPE Financing
every 12 shares of the combined company’s common stock outstanding will be combined and reclassified into 1 share of the combined company’s common stock
From December 31, 2022 to December 31,2023 Issuance of common stock upon vesting of Restricted Stock Units
From December 31, 2019 to December 31, 2020 Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
From June 30, 2020 to September 30, 2020 Issuance of common stock for cash,net of offering costs
From March 31, 2020 to June 30, 2020 Issuance of common stock and exercise of prefunded warrants for cash, net of offering costs
1.Common Stock Offered By the company 348,000 shares 2.The above discussion and table are based on 1,594,070 shares of common stock outstanding as of June 2, 2020
from June 30, 2019 to September 30, 2019 Issuance of common stock for cash,net of offering costs
from March 31, 2019 to June 30,2019 Issuance of common stock for cash,net of offering costs
from December 31, 2018 to April 4, 2019 Issuance of common stock for cash, net of offering costs Adjustment for fractional shares On April 3, 2019, ARCA biopharma, Inc. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company, as amended (the “Amendment”), to implement an eighteen-for-one reverse split of its common stock (the “Reverse Split”), as previously authorized and approved at a special meeting of the Company’s stockholders on October 18, 2018. The Reverse Split will be effective as of 5:01 p.m. (Eastern Time) on April 3, 2019, and the Company’s common stock will continue trading on the Nasdaq Capital Market on a post-split basis on April 4, 2019.
from December 31, 2017 to December 31, 2018 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
From December 31, 2017 to April 4, 2018 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2017 to March 19, 2018 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2016 to December 31, 2017 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2016 to July 31,2017 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
From December 31, 2016 to June 30, 2017 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2016 to March 31, 2017 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2015 to December 31, 2016 Issuance of common stock upon vesting of Restricted Stock Units
From December 31,2015 to September 30, 2016 Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2015 to March 15, 2016 Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2014 to December 31, 2015 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units Adjustment for fractional shares On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
From December 31, 2014 to September 30, 2015 Issuance of common stock for cash, net of offering costs Issuance of common stock upon vesting of Restricted Stock Units Adjustment for fractional shares On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
On September 3, 2015, the Company completed a 1-for-7 reverse stock split of its common stock.
from December 31, 2014 to June 30, 2015 Issuance of common stock for cash,net of offering costs Issuance of common stock upon vesting of Restricted Stock Units On June 16, 2015, we issued to the selling stockholders named below an aggregate of 42,021,579 shares of common stock and warrants to purchase an additional 16,808,632 shares of common stock in a private placement.
from December 31, 2014 to March 17, 2015 Issuance of common stock upon vesting of Restricted Stock Units
from December 31, 2013 to September 30, 2014 Issuance of common stock for cash, net of offering costs Issuance of common stock upon exercise of warrants for cash Issuance of common stock upon vesting of Restricted Stock Awards
From December 31, 2013 to May 9, 2014 Issuance of common stock for cash,net of offering costs Issuance of common stock upon exercise of warrants for cash
from December 31, 2012 to September 30, 2013 Issuance of common stock for cash, net of offering costs Adjustment for fractional shares Issuance of common stock upon exercise of warrants for cash Issuance of Series A convertible preferred stock, net of offering costs Conversion of preferred stock to common stock On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
from December 31, 2012 to June 30, 2013 Issuance of common stock for cash, net of offering costs Adjustment for fractional shares Issuance of common stock upon exercise of warrants for cash Issuance of Series A convertible preferred stock, net of offering costs Conversion of preferred stock to common stock On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.
On March 4, 2013, the Company completed a 1-for-6 reverse split of its common stock.The reverse stock split reduced the number of shares of ARCA’s issued and outstanding common stock from approximately 19.1 million shares to approximately 3.2 million shares.
1:3 stock split